Literature DB >> 6168292

Glycosyltransferases of the human cervical epithelium. II. Characterization of a CMP-N-acetylneuraminate: galactosyl-glycoprotein sialyltransferase.

P R Scudder, E N Chantler.   

Abstract

GMP-N-Acetylneuraminate: galactosyl-glycoprotein sialytransferase (CMP-N-acetylneuraminate: D-galactosyl-glycoprotein N-acetylneuraminyltransferase, EC 2.4.99.1) activity was identified in the human cervical epithelium. The enzyme has a pH optimum of 6.0, a temperature optimum of 28 degrees C, and demonstrates a partial requirement for Triton X-100. Michaelis constants for asialofetuin and CMP-N-acetyl[14C]neuraminic acid are 0.64 . 10(-5) M (expressed as the concentration of terminal galactose residues) and 2.05 . 10(-5) M, respectively. Sialytransferase demonstrated minimal affinity for the low molecular weight acceptors tested, and may have a requirement for a glycoprotein acceptor having a terminal N-acetyllactosamine (Gal beta (1 leads to 4)GlcNAc) type structure. Cytidine nucleotides are potent inhibitors of the sialyltransferase reaction; CMP acts as a competitive inhibitor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168292     DOI: 10.1016/0005-2744(81)90118-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Anaerobic growth and cytidine 5'-monophospho-N-acetylneuraminic acid act synergistically to induce high-level serum resistance in Neisseria gonorrhoeae.

Authors:  J V Frangipane; R F Rest
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

2.  In vitro and in vivo modification of Neisseria gonorrhoeae lipooligosaccharide epitope structure by sialylation.

Authors:  R E Mandrell; A J Lesse; J V Sugai; M Shero; J M Griffiss; J A Cole; N J Parsons; H Smith; S A Morse; M A Apicella
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

3.  Phase variation of lipopolysaccharide directs interconversion of invasive and immuno-resistant phenotypes of Neisseria gonorrhoeae.

Authors:  J P van Putten
Journal:  EMBO J       Date:  1993-11       Impact factor: 11.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.